Clinical Trials
37 trialsNCT03395197 2026-04-22
TALAPRO-2
Pfizer
Phase 3 Active not recruiting
NCT04497116 2025-10-21
TRESR
Repare Therapeutics
Phase 1/2 Completed
NCT03901469 2025-10-07
TNBC
Zenith Epigenetics
Phase 2 Terminated
NCT02912572 2025-07-10
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04849364 2025-05-31
PERSEVERE
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04187833 2025-01-14
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
Case Comprehensive Cancer Center
Phase 2 Completed
NCT04068831 2024-12-27
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04672460 2024-09-25
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT04173507 2024-09-03
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Completed
NCT03343054 2024-08-22
A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT03148795 2024-04-05
A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
Pfizer
Phase 2 Completed
NCT04690855 2023-12-04
TARA
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03330405 2023-10-13
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT04598321 2023-10-12
BrUOG 390: Neoadjuvant Treatment With Talazoparib
Brown University
Phase 1 Terminated
NCT04635631 2023-10-10
STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
Pfizer
Phase 1 Completed
NCT03565991 2023-09-25
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
Pfizer
Phase 2 Terminated
NCT03642132 2023-04-06
JAVELIN OVARIAN PARP100
Pfizer
Phase 3 Terminated
NCT02878785 2023-03-29
1565GCC
University of Maryland, Baltimore
Phase 1/2 Completed
NCT02401347 2023-02-21
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
Stanford University
Phase 2 Completed
NCT02921919 2022-08-24
Open-Label Extension and Safety Study of Talazoparib
Pfizer
Phase 2 Completed
NCT02282345 2022-07-06
Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03875313 2022-02-17
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Calithera Biosciences, Inc
Phase 1/2 Terminated
NCT03637491 2022-01-26
A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT01945775 2022-01-20
EMBRACA
Pfizer
Phase 3 Completed
NCT03499353 2021-11-09
Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Pfizer
Phase 2 Terminated
NCT04052204 2021-10-14
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT03077607 2021-06-30
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT03377556 2021-06-23
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT02116777 2021-03-26
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02997176 2021-02-25
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
Pfizer
Phase 1 Completed
NCT01989546 2021-02-23
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02997163 2021-01-05
An Open-Label Pharmacokinetics and Safety Study of Talazoparib
Pfizer
Phase 1 Completed
NCT02326844 2020-08-18
BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03042910 2019-12-17
A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT02034916 2019-10-14
ABRAZO
Pfizer
Phase 2 Terminated
NCT01286987 2019-01-10
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Pfizer
Phase 1 Completed
NCT03070548 2018-12-17
A Study of Talazoparib in Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed